. 2020 Aug 26;10(8):e038074. doi: 10.1136/bmjopen-2020-038074

Table 1.

Inclusion and exclusion criteria

	Exclusion criteria
Patients who meet all the following requirements. Patients diagnosed with coronary heart disease who met at least one of the following diagnostic criteria¹: (1) a clear history of myocardial infarction; (2) prior coronary revascularisation; (3) coronary angiography or coronary angiography suggesting at least one coronary artery stenosis with catheter stenosis ≥50%; (4) cardiac MRI or radionuclide myocardial perfusion imaging to confirm myocardial ischaemia in the patient having coronary heart disease. Patients complying with the diagnosis of UA and having at least one of the following conditions¹⁹: (1) ECG with a transient or persistent ST-segment depression of 0.1 mV and even more on one or more leads²⁰; (2) thrombolysis in myocardial infarction risk score ≥3.²¹ Patients receiving dual antiplatelet therapy (aspirin+clopidogrel). Patients aged 40–75 years, irrespective of sex. Patients willing to accept the drug treatment and provide written informed consent, conforming to the relevant regulations of good clinical practice.	Patients with cardiac function class IV (New York Heart Association cardiac function grading); or patients at a high risk of unstable angina short-term risk stratification. Patients with uncontrolled grade III hypertension having systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg; severe cardiopulmonary insufficiency; severe arrhythmia; severe primary diseases of the liver, kidney and haematopoietic system; or serious diseases (such as tumours) and mental diseases. Patients also having other clinical conditions that might increase the risk of bleeding, such as a history of important organ bleeding in the last 6 months (such as intracerebral haemorrhage and upper gastrointestinal bleeding), decreased platelet count, abnormal coagulation function and recent active bleeding. Patients with abnormal function indexes of the liver and kidney(blood alanine aminotransferase and aspartate aminotransferase level more than two times the upper normal reference range; glomerular filtration rate (GFR) <60 mL/(min ×1.73 m²)). Simplified modification of diet in renal disease formula: GFR (mL/(min ×1.73 m²))= 186.3 × serum creatinine (Scr)^–1.154 × (age) ^–0.203 × (0.742 female); Scr in mg/dL and age in years. Patients who planned to undergo revascularisation (PCI or coronary artery bypass grafting) recently. Patients allergic to a variety of foods, or with known allergy to study drugs, including their components. Patients pregnant, preparing for pregnancy or lactating. Patients participating in other clinical trials during the same period. Patients considered inappropriate to participate in this study.

Exclusion criteria

Patients who meet all the following requirements.
Patients diagnosed with coronary heart disease who met at least one of the following diagnostic criteria¹: (1) a clear history of myocardial infarction; (2) prior coronary revascularisation; (3) coronary angiography or coronary angiography suggesting at least one coronary artery stenosis with catheter stenosis ≥50%; (4) cardiac MRI or radionuclide myocardial perfusion imaging to confirm myocardial ischaemia in the patient having coronary heart disease.
Patients complying with the diagnosis of UA and having at least one of the following conditions¹⁹: (1) ECG with a transient or persistent ST-segment depression of 0.1 mV and even more on one or more leads²⁰; (2) thrombolysis in myocardial infarction risk score ≥3.²¹
Patients receiving dual antiplatelet therapy (aspirin+clopidogrel).
Patients aged 40–75 years, irrespective of sex.
Patients willing to accept the drug treatment and provide written informed consent, conforming to the relevant regulations of good clinical practice.

Patients with cardiac function class IV (New York Heart Association cardiac function grading); or patients at a high risk of unstable angina short-term risk stratification.
Patients with uncontrolled grade III hypertension having systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg; severe cardiopulmonary insufficiency; severe arrhythmia; severe primary diseases of the liver, kidney and haematopoietic system; or serious diseases (such as tumours) and mental diseases.
Patients also having other clinical conditions that might increase the risk of bleeding, such as a history of important organ bleeding in the last 6 months (such as intracerebral haemorrhage and upper gastrointestinal bleeding), decreased platelet count, abnormal coagulation function and recent active bleeding.
Patients with abnormal function indexes of the liver and kidney(blood alanine aminotransferase and aspartate aminotransferase level more than two times the upper normal reference range; glomerular filtration rate (GFR) <60 mL/(min ×1.73 m²)).
Simplified modification of diet in renal disease formula: GFR (mL/(min ×1.73 m²))= 186.3 × serum creatinine (Scr)^–1.154 × (age) ^–0.203 × (0.742 female); Scr in mg/dL and age in years.
Patients who planned to undergo revascularisation (PCI or coronary artery bypass grafting) recently.
Patients allergic to a variety of foods, or with known allergy to study drugs, including their components.
Patients pregnant, preparing for pregnancy or lactating.
Patients participating in other clinical trials during the same period.
Patients considered inappropriate to participate in this study.

PCI, percutaneous coronary intervention.